{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-25-000009","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.619624+00:00","generated_at":"2026-05-25T23:42:15.519691+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amneal reports Q4 revenue $731M (+18% YoY), FY24 revenue $2.79B (+17%); guides FY25 $3.0-3.1B","bullets":["Q4 2024 GAAP net loss $31M ($0.10 diluted loss per share); adjusted net income $40M, adjusted EBITDA $155M.","Full year 2024 net revenue $2.79B (+17% YoY); GAAP net loss $117M; adjusted EBITDA $627M (+12% YoY).","All three segments (Affordable Medicines, AvKARE, Specialty) grew double-digits in FY24; CREXONT launched successfully.","FY25 guidance: net revenue $3.0-$3.1B, adjusted EBITDA $650-$675M; net leverage reduced to 3.9x a year ahead of target."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-25-000009","json":"https://secwatch.observer/filing/0001723128-25-000009.json","markdown":"https://secwatch.observer/filing/0001723128-25-000009.md","text":"https://secwatch.observer/filing/0001723128-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000009/0001723128-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000009/amrx-20250228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:42:15.519691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}